4//SEC Filing
Hardiman Roy C. 4
Accession 0001209191-20-052225
CIK 0001510487other
Filed
Sep 27, 8:00 PM ET
Accepted
Sep 28, 5:14 PM ET
Size
16.6 KB
Accession
0001209191-20-052225
Insider Transaction Report
Form 4
Hardiman Roy C.
Chief Business Officer
Transactions
- Disposition from Tender
Common Stock
2020-09-28$100.00/sh−117,761$11,776,100→ 0 total - Disposition from Tender
Common Stock
2020-09-28$100.00/sh−1,916$191,600→ 0 total(indirect: See footnote) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−11,519→ 0 totalExercise: $7.27Exp: 2027-12-13→ Common Stock (11,519 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−44,034→ 0 totalExercise: $11.35Exp: 2028-08-23→ Common Stock (44,034 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−60,000→ 0 totalExercise: $35.42Exp: 2029-02-28→ Common Stock (60,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−55,000→ 0 totalExercise: $67.31Exp: 2030-03-04→ Common Stock (55,000 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes.
- [F2]Shares indirectly held by Roy Hardiman, as a fiduciary for his child, of which the Reporting Person may be deemed to share voting and dispositive power over these shares.
- [F3]Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Documents
Issuer
Principia Biopharma Inc.
CIK 0001510487
Entity typeother
Related Parties
1- filerCIK 0001506218
Filing Metadata
- Form type
- 4
- Filed
- Sep 27, 8:00 PM ET
- Accepted
- Sep 28, 5:14 PM ET
- Size
- 16.6 KB